WS-384

WS-384 is a dual LSD1 and DCN1-UBC12 protein-protein interaction inhibitor with oral activity, with IC50 values of 338.79 nM and 14.81 nM, respectively. WS-384 possesses anticancer activity and can cause cell cycle arrest, DNA damage, and induce apoptosis. WS-384 can be used in the research of non-small cell lung cancer (NSCLC) [1].

Product Specifications

CAS Number

[2247544-03-0]

UNSPSC

12352005

Target

Apoptosis; Caspase; DNA/RNA Synthesis; E1/E2/E3 Enzyme; Histone Demethylase

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ws-384.html

Purity

98.23

Solubility

DMSO : 17.86 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

BrC1=CC=C(CSC2=NN3C(SC4=NN=NN4CCN(C)C)=CC(C)=NC3=N2)C=C1.Cl

Molecular Formula

C18H21BrClN9S2

Molecular Weight

542.91

References & Citations

[1]Li A, et al. Discovery of WS-384, a first-in-class dual LSD1 and DCN1-UBC12 protein-protein interaction inhibitor for the treatment of non-small cell lung cancer. Biomed Pharmacother. 2024;173:116240.